NO20064603L - Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer. - Google Patents

Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer.

Info

Publication number
NO20064603L
NO20064603L NO20064603A NO20064603A NO20064603L NO 20064603 L NO20064603 L NO 20064603L NO 20064603 A NO20064603 A NO 20064603A NO 20064603 A NO20064603 A NO 20064603A NO 20064603 L NO20064603 L NO 20064603L
Authority
NO
Norway
Prior art keywords
antagonists
treatment
liver diseases
cbi receptor
preparations useful
Prior art date
Application number
NO20064603A
Other languages
English (en)
Norwegian (no)
Inventor
Sophie Lotersztajn
Ariane Mallat
Pascale Grenard
Boris Julien
Jeanne Tran Van Nhieu
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20064603L publication Critical patent/NO20064603L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20064603A 2004-03-09 2006-10-09 Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer. NO20064603L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04290633A EP1574211A1 (en) 2004-03-09 2004-03-09 Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
PCT/EP2005/003285 WO2005084652A2 (en) 2004-03-09 2005-03-08 Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases

Publications (1)

Publication Number Publication Date
NO20064603L true NO20064603L (no) 2006-10-09

Family

ID=34814417

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064603A NO20064603L (no) 2004-03-09 2006-10-09 Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer.

Country Status (27)

Country Link
US (2) US8236763B2 (zh)
EP (3) EP1574211A1 (zh)
JP (1) JP2007527893A (zh)
KR (1) KR20070026415A (zh)
CN (1) CN1929828A (zh)
AR (1) AR048087A1 (zh)
AT (1) ATE520393T1 (zh)
AU (1) AU2005218937B2 (zh)
BR (1) BRPI0508560A (zh)
CA (1) CA2557976A1 (zh)
CY (1) CY1112078T1 (zh)
DK (1) DK1725223T3 (zh)
ES (1) ES2371552T3 (zh)
HK (1) HK1094674A1 (zh)
IL (1) IL177465A0 (zh)
MA (1) MA28454B1 (zh)
MX (1) MXPA06010287A (zh)
NO (1) NO20064603L (zh)
PL (1) PL1725223T3 (zh)
PT (1) PT1725223E (zh)
RU (1) RU2402328C2 (zh)
SI (1) SI1725223T1 (zh)
TN (1) TNSN06272A1 (zh)
TW (1) TWI337540B (zh)
UA (1) UA94025C2 (zh)
WO (1) WO2005084652A2 (zh)
ZA (1) ZA200607159B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
US7875647B2 (en) 2006-09-29 2011-01-25 Green Cross Corporation Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists
ES2542042R1 (es) * 2010-07-15 2015-10-06 Oleg Iliich Epshtein Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
US20120288442A1 (en) * 2011-05-11 2012-11-15 Atomic Energy Council-Institute Of Nuclear Energy Research Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
IN2015DN03733A (zh) 2012-11-13 2015-09-18 Us Health
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
MX2016012403A (es) 2014-03-27 2017-06-14 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano.
CA2948349C (en) 2014-05-09 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
CA3000167A1 (en) 2015-09-30 2017-04-06 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
WO2017184412A1 (en) * 2016-04-18 2017-10-26 Eli Lilly And Company Purine cannabinoid agonist for treating nonalcoholic steatohepatitis and fibrosis

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
AT394493B (de) * 1989-05-11 1992-04-10 Homosan Ag Pharmazeutisches praeparat zur behandlung von lebererkrankungen
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
FR2713225B1 (fr) 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US6143752A (en) * 1997-08-01 2000-11-07 Oren; Ran Method for preventing or arresting liver damage in humans
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US7056890B2 (en) * 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
FR2805810B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation
FR2805818B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
FR2805817B1 (fr) 2000-03-03 2002-04-26 Aventis Pharma Sa Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
FR2809621B1 (fr) 2000-05-12 2002-09-06 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles comme antidiarrheiques
AU2001275127A1 (en) * 2000-06-01 2001-12-11 The Mclean Hospital Corporation Method for treating alcohol intoxication and alcohol abuse
US6632647B2 (en) * 2000-07-11 2003-10-14 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis against organ fibrosis
WO2003063781A2 (en) * 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
FR2837706A1 (fr) 2002-03-28 2003-10-03 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
WO2003087037A1 (en) * 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
CA2481313A1 (en) 2002-04-12 2003-10-23 Merck & Co., Inc. Bicyclic amides
US20040034968A1 (en) * 2002-06-14 2004-02-26 Hufcor, Inc. 360 Degree hinge and door closure apparatus
SE0202242D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Compounds
SE0202240D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Genes
US7091216B2 (en) * 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
FR2849032B1 (fr) * 2002-12-23 2006-04-28 Sanofi Synthelabo Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
EP1663215A1 (en) * 2003-09-02 2006-06-07 Solvay Pharmaceuticals GmbH Novel medical use of selective cb1- receptor antagonists
US7320805B2 (en) * 2003-10-01 2008-01-22 Institut National De La Sante Et De La Recherche Medicale CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
WO2005039579A1 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
FR2861303A1 (fr) 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
GB0403780D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
PL1725223T3 (pl) 2012-01-31
EP2305220A3 (en) 2011-05-18
RU2402328C2 (ru) 2010-10-27
EP1725223A2 (en) 2006-11-29
RU2006134707A (ru) 2008-04-20
WO2005084652A2 (en) 2005-09-15
US20120329833A1 (en) 2012-12-27
AU2005218937A1 (en) 2005-09-15
ES2371552T3 (es) 2012-01-05
MXPA06010287A (es) 2007-02-14
EP1725223B1 (en) 2011-08-17
KR20070026415A (ko) 2007-03-08
EP2305220B1 (en) 2014-07-30
MA28454B1 (fr) 2007-03-01
JP2007527893A (ja) 2007-10-04
IL177465A0 (en) 2007-07-04
TNSN06272A1 (en) 2007-12-03
AR048087A1 (es) 2006-03-29
TW200534851A (en) 2005-11-01
EP2305220A2 (en) 2011-04-06
US20080214449A1 (en) 2008-09-04
WO2005084652A3 (en) 2005-12-08
EP1574211A1 (en) 2005-09-14
BRPI0508560A (pt) 2007-08-14
US8604060B2 (en) 2013-12-10
ATE520393T1 (de) 2011-09-15
CA2557976A1 (en) 2005-09-15
UA94025C2 (ru) 2011-04-11
DK1725223T3 (da) 2011-11-28
HK1094674A1 (en) 2007-05-18
CY1112078T1 (el) 2015-11-04
AU2005218937B2 (en) 2011-07-07
CN1929828A (zh) 2007-03-14
US8236763B2 (en) 2012-08-07
TWI337540B (en) 2011-02-21
ZA200607159B (en) 2008-02-27
SI1725223T1 (sl) 2012-01-31
PT1725223E (pt) 2011-12-02

Similar Documents

Publication Publication Date Title
NO20064603L (no) Anvendelse av antagonister av CBI-reseptoren av preparat anvendelig for behandling av leversykdommer.
MA28105A1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des dyslipidemies et des maladies associees aux dyslipidemies et/ou a l'obesite
HK1051140A1 (en) Use of central cannabinoid receptor antagonist forpreparing medicines designed to facilitate smokingcessation.
NO20033165D0 (no) (+)-1-(3,4-diklorfenyl)-3-azabicyklo[3.1.0]heksan, sammensetning og anvendelse derav
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
IL277777A (en) N-(cyclopropylmethyl)-5-(methylsulfonyl)-N-{1-[1-(pyrimidin-2-yl)-H1-1, 2, 4-triazol-5-yl]ethyl}benzamide derivatives and pyridinecarboxamide derivatives Compatible as pest killers
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20054082L (no) Pyrazol`1,5-A! 1,3,5! triazinderivater som kannabinoidreseptorligander
IS2759B (is) CGRP-viðtakamótlyf, lyfjaefnablanda og notkun á efnablöndunum til framleiðslu á lyfi
DK1756064T3 (da) Pyrazolderivater, sammensætninger indeholdende sådanne forbindelser og anvendelsesmetoder
MX2007000036A (es) Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
NO20055256D0 (no) 4-(4-heterosyklylalkoksy)fenyl)-1-(heterosyklyl-karbonyl)piperidinderivater og beslektede forbindelser som histamin H3-antagonister for behandling av neurologiske sykdommer som Alzheimers
ATE450508T1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
LU92238I2 (fr) 1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one ou l'un de sls physiologiquement acceptables. autre formulation du composé chimiqu e:1-(4-Chlorophenyl)4-morpholino-imidazolin-2-one
IS2641B (is) 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
ATE478052T1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor- antagonisten zur behandlung von psychosen und neurologischen störungen
DK1828182T3 (da) Terapeutiske pyrazol[3,4-B]pyridiner og indazoler
TW200616950A (en) Synthesis of indole analogs of 1-benzyl-3-(5'-hydroxymethyl-2'-furyl)indazole (yc-1) as anti-platelet agents
NO20052197D0 (no) Fremgangsmate for fremstilling av pyrazol
DE602004031726D1 (de) Indazole mit analgetischer aktivität
ES2328328A1 (es) Polimorfo alfa de una pirazolina sustituida, su preparacion y su uso como medicamento
WO2004100895A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
ITRM20020109V0 (it) Il dado dell'amore.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application